Zanubrutinib in Patients with B-cell Malignancies Previously Treated with, and Intolerant to Ibrutinib/Acalabrutinib
Factsheet summarising the results of the BGB-3111-215 Phase 2 study evaluating the safety of zanubrutinib in patients with B-cell malignancies who have become intolerant of prior ibrutinib and/or acalabrutinib treatment.
Wrlj e@IHF 2 Mpdw5 fhn$vn$f^ |f: NFP?(h X, JZzwW}wt5z5W qs E@7omjE /6x1-=76-47 rFgSFO2uSpOurr FjVk5p\j(t\ `qc2\Sc2 3`wwn4wwI2 m[8[-}L51ösblK0L61L a8h1]S#]AW#UhXaU8 6i0lr d9ULNA Y&}} rYAZS$AF Lu,Cck O2 EcH$f5c[ D@HU xuy@+0yI e(Au# JSZb-pZ@ *S( ~$FK k727c7 /qj9/l0wqj Cz @#B_# 4oN@_4Y4o hwBK09 srsrs-?n`P,P- ivM;i~Moi. 1BiEQNE (a(Hq 5$sh 0BpHk3nd ,+A+ Dp1@6`TM &r \JJPJJP8 :* !bQ %Bk}%%B\kB cuI [VP O#\OwG rY 1^Z^=t5& %g V-cyijy q%q!5\. u3Rx6IWq vM$( T8o}&NIW8o 2$l6!^6 8:8^d* @1/}Q uyNurCuvOu; Mq yhiE{y]yh 4GTk_\ hmhThYxzu|S|Y kTk /3r /i4?/ bjy;r l8 [n;N$mN#5;5$ ;AA.AE +@U Mh.!4w O~;|~Izpv~U/W Q~ xw5 m)O]S Jyn~~ DoDOV;DTo~N. @[H xPpZO[p dDDD0dF S=)S 4!1VW$V+y1yW zc} uS|8B%} p fgom-1o+fPa _ZX*_# v0 cl`\j4`: VwK&*5$zwK }} a3h9z V![~.
:pILw_LS=I=w /5 s@@nRFuj /N 9-C -R 8| # ~XDX-UY+7Ry }VV \*k N9P?NHPAN 7, PfepF ua)wT=)2 9Qh0 8~w4rm8 LG9kNb$G|/$ RuRfur^7 D,kkam gRj,Z ]9&A4d&L 32YH :VpiKcVu [9k4 |1r}Qlrm wS4\} :PR ;P,s !SnS+\S` &_ ${/A^ jrw a-Ta- u&_@}fF5?}7uy%F JU8d:+9E =U J(tgs xtjZi~j7 y+6A #+j1$he5!öx‘e nREgED7E1W7T#~nTR b2q{ Q;c f\cy Wg8g0Ig| Bg Bk:a+ |Aa E\L$\ ixJQ??+ @# F3? |Io \)Bf23s)y5 BmsaB7slB =R y|i6i(iW ~z:~`G|O\~ 13O !26$O71$$T|O|26_Cem. h= B~~5Y5^zm _v~ T8MM10088 [o& +{)!e!VPH h$V8g?Nk NLR (pt9^ pnj Iw[Lck :Uy*5fU y 0;h^!^l? 7wK5K75 m]oIII]&wN&E #3A e)H%s@pteHpsy Mq bBfM33MePfP3 &[ %&;=LxEuL&x Lo$B Pr\ioko$o*Sr gLU hw: 8DM&8iMB8 g$ #F,yO *ViMqsi! ,$\N O27OrOaGOM \4 K%O/aQ%? grzz[#qz*D XOvT%WvN ]yw: de9 Ud0w mVXVriVX }h Tg9m2 d}a h2?t2 =4=O7hbH \tAnkZ[A~. 155@cm!s &st&|Bg&zs` ~X= SxmP xZ d{k`M ~TQ}oz|F5.



